Moreover, RABL6A is a potent oncoprotein that controls many druggable cancer targets besides CDK4/6 and MEK, including Myc (Figure 1), PP2A-Akt-mTOR, and receptor tyrosine kinase pathways like VEGFR and EGFR [11, 12, 16]. This evidence concerns the gene CDK4 and cancer.